Literature DB >> 15572669

The CRM1 nuclear export receptor controls pathological cardiac gene expression.

Brooke C Harrison1, Charles R Roberts, David B Hood, Meghan Sweeney, Jody M Gould, Erik W Bush, Timothy A McKinsey.   

Abstract

Diverse pathological insults trigger a cardiac remodeling process during which myocytes undergo hypertrophy, with consequent decline in cardiac function and eventual heart failure. Multiple transcriptional regulators of pathological cardiac hypertrophy are controlled at the level of subcellular distribution. For example, prohypertrophic transcription factors belonging to the nuclear factor of activated T cells (NFAT) and GATA families are subject to CRM1-dependent nuclear export but are rapidly relocalized to the nucleus in response to cues for hypertrophic growth. Here, we demonstrate that the antihypertrophic chromatin-modifying enzyme histone deacetylase 5 (HDAC5) is shuttled out of the cardiomyocyte nucleus via a CRM1-mediated pathway in response to diverse signals for hypertrophy. CRM1 antagonists block the agonist-mediated nuclear export of HDAC 5 and repress pathological gene expression and associated hypertrophy of cultured cardiomyocytes. Conversely, CRM1 activity is dispensable for nonpathological cardiac gene activation mediated by thyroid hormone and insulin-like growth factor 1, agonists that fail to trigger the nuclear export of HDAC5. These results suggest a selective role for CRM1 in derepression of pathological cardiac genes via its neutralizing effects on antihypertrophic factors such as HDAC5. Pharmacological approaches targeting CRM1-dependent nuclear export in heart muscle may have salutary effects on cardiac function by suppressing maladaptive changes in gene expression evoked by stress signals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15572669      PMCID: PMC533968          DOI: 10.1128/MCB.24.24.10636-10649.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  67 in total

Review 1.  Nuclear targeting signal recognition: a key control point in nuclear transport?

Authors:  D A Jans; C Y Xiao; M H Lam
Journal:  Bioessays       Date:  2000-06       Impact factor: 4.345

Review 2.  Mechanics of left ventricular systolic and diastolic function in physiologic hypertrophy of the athlete's heart.

Authors:  S D Colan
Journal:  Cardiol Clin       Date:  1997-08       Impact factor: 2.213

3.  Regulation of gene expression by cyclic GMP-dependent protein kinase requires nuclear translocation of the kinase: identification of a nuclear localization signal.

Authors:  T Gudi; S M Lohmann; R B Pilz
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  Downregulation of sarcoplasmic reticulum Ca(2+)-ATPase during progression of left ventricular hypertrophy.

Authors:  M Qi; T R Shannon; D E Euler; D M Bers; A M Samarel
Journal:  Am J Physiol       Date:  1997-05

5.  Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice.

Authors:  M C Delaughter; G E Taffet; M L Fiorotto; M L Entman; R J Schwartz
Journal:  FASEB J       Date:  1999-11       Impact factor: 5.191

6.  Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region.

Authors:  N Kudo; N Matsumori; H Taoka; D Fujiwara; E P Schreiner; B Wolff; M Yoshida; S Horinouchi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 7.  Genetic dissection of cardiac growth control pathways.

Authors:  W R MacLellan; M D Schneider
Journal:  Annu Rev Physiol       Date:  2000       Impact factor: 19.318

8.  CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.

Authors:  R Passier; H Zeng; N Frey; F J Naya; R L Nicol; T A McKinsey; P Overbeek; J A Richardson; S R Grant; E N Olson
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

9.  Deletion of cytosolic phospholipase A2 promotes striated muscle growth.

Authors:  Syed Haq; Heiko Kilter; Ashour Michael; Jingzang Tao; Eileen O'Leary; Xio Ming Sun; Brian Walters; Kausik Bhattacharya; Xin Chen; Lei Cui; Michele Andreucci; Anthony Rosenzweig; J Luis Guerrero; Richard Patten; Ronglih Liao; Jeffery Molkentin; Michael Picard; Joseph V Bonventre; Thomas Force
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

10.  A20 is dynamically regulated in the heart and inhibits the hypertrophic response.

Authors:  Stuart A Cook; Mikhail S Novikov; Youngkeun Ahn; Takashi Matsui; Anthony Rosenzweig
Journal:  Circulation       Date:  2003-08-04       Impact factor: 29.690

View more
  32 in total

Review 1.  Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.

Authors:  Timothy A McKinsey; Eric N Olson
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 2.  Class II histone deacetylases: from sequence to function, regulation, and clinical implication.

Authors:  Xiang-Jiao Yang; Serge Grégoire
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

3.  Regulation of cardiac stress signaling by protein kinase d1.

Authors:  Brooke C Harrison; Mi-Sung Kim; Eva van Rooij; Craig F Plato; Philip J Papst; Rick B Vega; John A McAnally; James A Richardson; Rhonda Bassel-Duby; Eric N Olson; Timothy A McKinsey
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

4.  Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.

Authors:  Christopher E Pedigo; Gloria Michelle Ducasa; Farah Leclercq; Alexis Sloan; Alla Mitrofanova; Tahreem Hashmi; Judith Molina-David; Mengyuan Ge; Mariann I Lassenius; Carol Forsblom; Markku Lehto; Per-Henrik Groop; Matthias Kretzler; Sean Eddy; Sebastian Martini; Heather Reich; Patricia Wahl; GianMarco Ghiggeri; Christian Faul; George W Burke; Oliver Kretz; Tobias B Huber; Armando J Mendez; Sandra Merscher; Alessia Fornoni
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

5.  Histone deacetylase 5 limits cocaine reward through cAMP-induced nuclear import.

Authors:  Makoto Taniguchi; Maria B Carreira; Laura N Smith; Benjamin C Zirlin; Rachael L Neve; Christopher W Cowan
Journal:  Neuron       Date:  2012-01-12       Impact factor: 17.173

6.  Fatty acids identified in the Burmese python promote beneficial cardiac growth.

Authors:  Cecilia A Riquelme; Jason A Magida; Brooke C Harrison; Christopher E Wall; Thomas G Marr; Stephen M Secor; Leslie A Leinwand
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

7.  Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Authors:  Alexander Grabner; Ansel P Amaral; Karla Schramm; Saurav Singh; Alexis Sloan; Christopher Yanucil; Jihe Li; Lina A Shehadeh; Joshua M Hare; Valentin David; Aline Martin; Alessia Fornoni; Giovana Seno Di Marco; Dominik Kentrup; Stefan Reuter; Anna B Mayer; Hermann Pavenstädt; Jörg Stypmann; Christian Kuhn; Susanne Hille; Norbert Frey; Maren Leifheit-Nestler; Beatrice Richter; Dieter Haffner; Reimar Abraham; Johannes Bange; Bianca Sperl; Axel Ullrich; Marcus Brand; Myles Wolf; Christian Faul
Journal:  Cell Metab       Date:  2015-10-01       Impact factor: 27.287

8.  Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy.

Authors:  Xiangbin Xu; Chang-Hoon Ha; Chelsea Wong; Weiye Wang; Angelika Hausser; Klaus Pfizenmaier; Eric N Olson; Timothy A McKinsey; Zheng-Gen Jin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-09-06       Impact factor: 8.311

Review 9.  A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease.

Authors:  Lillianne H Wright; Donald R Menick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-20       Impact factor: 4.733

10.  miRNA expression in the failing human heart: functional correlates.

Authors:  Carmen Sucharov; Michael R Bristow; J David Port
Journal:  J Mol Cell Cardiol       Date:  2008-05-15       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.